Tags

Type your tag names separated by a space and hit enter

[Thromboxane A2 synthetase inhibitor in asthma therapy].
Nihon Rinsho 1996; 54(11):3034-9NR

Abstract

Thromboxane A2(TXA2), a platelet aggregator and vasoconstricter, has been implicated as a potential mediator of bronchial asthma. TXA2 induces potent contraction of airway smooth muscles and airway hyperresponsiveness. OKY-046 (ozagrel hydrochloride) is a specific inhibitor of TXA2 synthetase and a new antiasthmatic agent. In a phase III study ozagrel has shown significantly higher effect in ameliorating the asthma symptoms and reduced the dose of concomitant steroid therapy compared to azelastine hydrochloride. Both basical and clinical studies showed that TXA2 synthetase inhibitor is effective on airway hyperresponsiveness. In this review the role of TXA2 synthetase inhibitor in current asthma therapy, which is based on the Japanese guideline of allergic disorders, was discussed.

Authors+Show Affiliations

2nd Department of Internal Medicine, Nagoya University School of Medicine.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

8950950

Citation

Machida, K, et al. "[Thromboxane A2 Synthetase Inhibitor in Asthma Therapy]." Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 54, no. 11, 1996, pp. 3034-9.
Machida K, Takagi K, Horiba M. [Thromboxane A2 synthetase inhibitor in asthma therapy]. Nippon Rinsho. 1996;54(11):3034-9.
Machida, K., Takagi, K., & Horiba, M. (1996). [Thromboxane A2 synthetase inhibitor in asthma therapy]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 54(11), pp. 3034-9.
Machida K, Takagi K, Horiba M. [Thromboxane A2 Synthetase Inhibitor in Asthma Therapy]. Nippon Rinsho. 1996;54(11):3034-9. PubMed PMID: 8950950.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Thromboxane A2 synthetase inhibitor in asthma therapy]. AU - Machida,K, AU - Takagi,K, AU - Horiba,M, PY - 1996/11/1/pubmed PY - 1996/11/1/medline PY - 1996/11/1/entrez SP - 3034 EP - 9 JF - Nihon rinsho. Japanese journal of clinical medicine JO - Nippon Rinsho VL - 54 IS - 11 N2 - Thromboxane A2(TXA2), a platelet aggregator and vasoconstricter, has been implicated as a potential mediator of bronchial asthma. TXA2 induces potent contraction of airway smooth muscles and airway hyperresponsiveness. OKY-046 (ozagrel hydrochloride) is a specific inhibitor of TXA2 synthetase and a new antiasthmatic agent. In a phase III study ozagrel has shown significantly higher effect in ameliorating the asthma symptoms and reduced the dose of concomitant steroid therapy compared to azelastine hydrochloride. Both basical and clinical studies showed that TXA2 synthetase inhibitor is effective on airway hyperresponsiveness. In this review the role of TXA2 synthetase inhibitor in current asthma therapy, which is based on the Japanese guideline of allergic disorders, was discussed. SN - 0047-1852 UR - https://www.unboundmedicine.com/medline/citation/8950950/[Thromboxane_A2_synthetase_inhibitor_in_asthma_therapy]_ L2 - http://www.diseaseinfosearch.org/result/633 DB - PRIME DP - Unbound Medicine ER -